Bacterial conjunctivitis appears to resolve more rapidly when treated with appropriate topical antimicrobial agents. In this multicenter, randomized, double-blind study of efficacy and safety, patients with presumed bacterial external eye infections were assigned to topical therapy with 0.3% norfloxacin or 0.3% tobramycin. A total of 120 patients were enrolled. Of the total, 65 had documented bacterial infections and were evaluable; 59 of these patients had bacterial conjunctivitis. All of the patients with documented infections were cured or improved regardless of the drug treatment regimen or in vitro susceptibility testing results. The most common bacteria isolated were Haemophilus influenzae, Streptococcus pneumoniae, alpha-hemolytic streptococci, Staphylococcus aureus, and Staphylococcus sp. No patients had serious adverse reactions attributed to their therapy. Norfloxacin ophthalmic solution seems to be a safe, effective, and appropriate agent for the treatment of bacterial external eye infections.
Bacterial conjunctivitis is a common and distressing infectious disease of children and adults. There is some evidence suggesting that topical antimicrobial therapy may shorten the course and reduce the morbidity of this often self-limited infection (5) . Many of the antimicrobial agents used in the treatment of bacterial conjunctivitis, including tobramycin, are not consistently active in vitro against all of the bacteria which commonly cause this infection, specifically Haemophilus influenzae, Streptococcus pneumoniae, and staphylococci (9) . These antimicrobial agents also are associated with a low but significant incidence of adverse effects, including inflammation, hypersensitivity, and punctate corneal erosions (9, 11, 17) . Norfloxacin, a quinoline compound recently licensed for oral administration for the treatment of urinary tract infections, does have an in vitro spectrum which includes these organisms, although its activity against S. pneumoniae is only moderate. Norfloxacin is active against enteric gram-negative rods and Pseudomonas aeruginosa, including gentamicin-resistant strains. These organisms also are occasionally responsible for conjunctivitis (7, 8, 15) . Like other quinolines, norfloxacin is bacteriocidal by affecting bacterial DNA gyrase, and it is associated with a low rate of development of resistance. Norfloxacin has generally been well tolerated when administered in oral form and after installation of the topical preparation into the eyes of normal subjects (Merck Sharp & Dohme, West Point, Pa., unpublished data). Because of its broad spectrum of activity and apparent lack of serious side effects, norfloxacin appeared to be a drug well suited for the treatment of conjunctivitis. Animal studies also suggest that norfloxacin is effective (4) . The purpose of this multicenter, randomized, double-blind study was to compare the safety and efficacy of topical ophthalmic norfloxacin versus topical tobramycin in the treatment of patients with presumed bacterial conjunctivitis and other external ocular infections. At one site (LDS Hospital), we Patients were examined by an ophthalmologist, who obtained specimens for culture from the infected eye or eyes. In patients with conjunctivitis, a moistened calcium alginate swab (Transette 1; Spectrum Diagnostics) was rotated in the lower conjunctival fornix from the nasal margin to the temporal margin and then back to the nasal margin. In patients with blepharitis, a moistened swab was rotated along the lash margin of the eyelid in a similar fashion. Additionally, at one center (LDS Hospital) similar specimens were obtained from the uninfected eyes of patients, and a herpes Transette swab (Spectrum Diagnostics) was also used in the conjunctiva of both eyes.
The ophthalmologist scored symptoms and signs on a scale of 0 to 3, indicating absent, mild, moderate, or severe. The symptoms were blurred vision, photophobia, burning, tearing, foreign-body sensation, and itching. The signs were erythema, edema, or exudate involving the lids; infiltrates or fluorescein staining of the cornea; and hyperemia, edema, discharge, or follicles of the conjunctivae. The presence of papillae was reflected in the grading of hyperemia.
Patients were assigned by a random allocation schedule to receive a 5-ml vial of either norfloxacin 0.3% ophthalmic solution or tobramycin 0.3% ophthalmic solution. Patients were instructed to place one drop in the affected eye(s) every 2 h while awake on day 1 and then four times per day for 6 additional days.
The patients were to return for reexamination after 3 full days of therapy. The examination included a review of symptoms, test of visual acuity, and gross and slit-lamp examination. If no clinical improvement was noted, the patient was removed from the study and repeat specimens for bacterial culture were obtained as was done for the pretreatment examination. At least 12 to 36 h after the last administration of the test drug, the patients returned for a final examination and collection of specimens. At the final evaluation, patients were characterized as cured (signs and symptoms absent), improved (signs and symptoms decreased compared with those found at pretreatment), unimproved (no change in signs and symptoms from those found at pretreatment), or worsened (signs and symptoms increased compared with those found at pretreatment).
Quantitative bacterial cultures were performed by dissolving the calcium alginate swab in Calgon Ringer solution, inoculating a 1-ml portion on sheep blood and chocolate agar, and incubating the culture for 24 h in an atmosphere containing 4% CO2. Susceptibility testing was done by agar disk diffusion (12, 16) .
The swab specimens for nonbacterial pathogens were placed in 10% McCoy medium. The suspension was equally divided for chlamydia and virus culturing and for staining. Chlamydiae were sought by standard methods (10) . Virus cultures were inoculated on monkey kidney cells, HEp-2 cells, A549 cells, MRC-5 cells, human embryonic kidney cells, and mink lung cells and observed for cytopathic effect for 14 days. Mink lung cells were also stained with an immunoperoxidase stain at 18 h (14) .
Bacterial cultures were considered positive for a pathogen if they yielded any beta-hemolytic streptococci, S. pneumoniae, gram-negative bacilli, or Neisseria species; if they had at least 10 colonies of alpha-hemolytic streptococci, Staphylococcus aureus, or Branhamella catarrhalis; if they had at least 100 colonies of Bacillus species or of Staphylococcus species other than Staphylococcus aureus; or if they had at least 1,000 colonies of Corynebacterium species. (D. B. Jones, Cullen Eye Institute, Houston, Tex., personal communication). No other ocular treatments, including warm, moist compresses, were permitted during the course of this trial. If discharges on eyelids or lashes were annoying, they could be removed with a moist pad. Systemic antibiotic treatment was not permitted.
Patients enrolled in this study provided written informed consent, and the protocol was approved by the appropriate institutional review boards.
RESULTS
A total of 120 patients were enrolled in the study. Of these, 60 were assigned to receive norfloxacin and 60 were assigned to receive tobramycin. Two patients, both assigned to receive norfloxacin, were lost to follow-up. One had Staphylococcus aureus and alpha-hemolytic streptococci in pretreatment culture, and one had no pathogen recovered. One patient assigned to the tobramycin group was excluded from evaluation because he discontinued the drug on day 4 because of nervousness, nausea, and insomnia, which the ophthalmologist felt was not attributable to tobramycin. He had blepharoconjunctivitis with alpha-hemolytic streptococci and Staphylococcus sp. His eyes had improved when he stopped treatment.
One patient assigned to the norfloxacin group had conjunctivitis with no pathogen identified but was dropped from the study when a streptococcal pharyngitis necessitated systemic antibiotic treatment.
One patient assigned to receive norfloxacin, a 38-year-old male with H. influenzae conjunctivitis, was excluded because of concomitant use of oral erythromycin. Two other patients were excluded from analysis because it became apparent that their conjunctivitis was more likely attributable to a noninfectious cause. One had allergic conjunctivitis, and one had Reiter's syndrome. Both were assigned to receive norfloxacin. Thus, 54 patients assigned to norfloxacin and 59 patients assigned to tobramycin were evaluable.
Of the evaluable patients, 1 had blepharitis, 2 had keratoconjunctivitis, 10 had blepharoconjunctivitis, and 102 had conjunctivitis. A 31-year-old female patient with blepharitis and blepharoconjunctivitis had alpha-hemolytic streptococci recovered from her lid margin and conjunctiva. She was treated with norfloxacin and was clinically cured. The organism was resistant in vitro to norfloxacin, but posttherapy cultures showed suppression on the eyelid and eradication from the conjunctiva. She had no adverse reaction. A male infant had conjunctivitis caused by H. influenzae and blepharoconjunctivitis associated with H. influenzae, Staphylococcus aureus, and Staphylococcus sp. Treatment with tobramycin was followed by clinical cure and bacterial eradication. The two patients with keratoconjunctivitis, a male aged 21 years and a female aged 74 years, were both assigned to receive tobramycin. Neither grew a bacterial pathogen. Both had clinical resolution without adverse reactions. Of the 10 patients with blepharoconjunctivitis, 9 were female. The age range of the entire group was between 10 and 83 years. Six of the ten patients had pathogens recovered from eye swabs; these organisms included Pseudomonas cepacia, alpha-hemolytic streptococci, Staphylococcus aureus, Staphylococcus species, and H. influenzae. All six of the patients with bacterial pathogens were considered cured, as were three of four patients with no pathogens isolated. One patient with no pathogens recovered was considered worsened after therapy. All pathogens except alpha-hemolytic streptococci were susceptible to the agents the patients received. All of the pathogens, with the exception of a P. cepacia in a patient assigned to receive norfloxacin and an alpha-hemolytic streptococcus in a patient assigned to receive tobramycin, were eradicated.
Conjunctivitis was the most common condition encountered in our study and the one most appropriate for detailed All 59 patients with bacterial pathogens recovered were either cured or improved. In the norfloxacin-treated group, 14 of 17 patients with H. influenzae were cured, as were four of five patients with S. pneumoniae, three of three patients with Staphylococcus aureus, and two of two patients with alpha-hemolytic streptococci. One patient with Staphylococcus sp. was improved. In the tobramycin-treated group, all seven patients with H. influenzae were cured, as were eight patients with S. pneumoniae, four patients with Staphylococcus aureus, five patients with Staphylococcus sp., and three patients with gram-negative bacilli. Six of seven patients with alpha-hemolytic streptococci were cured. A total of 33 pathogens were isolated from the 30 patients treated with tobramycin.
Most patients with no bacterial pathogens isolated also did well. Of 23 such patients assigned to receive norfloxacin, 18 were cured, 4 were improved, and 1 was unimproved. In the tobramycin-treated group, 16 of 20 patients were cured, 3 were improved, and 1 was unimproved.
Included among patients with bacterial pathogens isolated were three patients from whom adenovirus was also recovered from one or both eyes. Two of these patients were assigned, to receive tobramycin and were cured. The other patient, who had an associated S. pneumoniae infection, was treated with norfloxacin and improved. One other patient with only adenovirus recovered received tobramycin and improved. One patient assigned to receive norfloxacin yielded herpes simplex virus only and was considered cured.
Bacteriologic outcomes were likewise very good and comparable in the two treatment groups. Approximately 80% of pathogens were eliminated after therapy (Table 3 ). All but one of the patients whose pathogens were suppressed or persistent were clinically cured. The exception was a patient with H. influenzae treated with norfloxacin, who was judged to be improved.
The data in Table 4 , from one center (LDS Hospital), relate recovery of pathogens as we defined them to the clinical status of eyes at the time of entry into the study. The results permit an evaluation of the criteria we used for designating bacterial pathogens. H. influenzae and S. pneumoniae were always or almost always isolated from an eye that was initially clinically involved or developed signs of inflammation shortly after the patient was entered into the study (see below). Alpha-hemolytic streptococci and Staphylococcus species of specified number were recovered only slightly more commonly from affected eyes than from unaffected eyes; when they were recovered, it was often in with conjunctivitis with that of normal controls have been Nine of 36 eyes that were normal at the time the patients done in pediatric patients, and the authors have reached entered the study became affected. Three of five eyes with S.
slightly different conclusions (2, 6; R. M. Levin, W. Ticknor, pneumoniae in the original culture, including the two with C. Jordan, and M. Grossman, J. Pediatr. 98:531, 1981). All other pathogens, became inflamed, were treated, and reagree that S. pneumoniae and H. influenzae are likely solved. One of two eyes initially unaffected but positive for pathogens since they are found significantly more often in alpha-hemolytic streptococci became involved during treataffected eyes. The assumption that H. influenzae is not an ment and responded to therapy. Of 27 originally unaffected important pathogen in adults is refuted in our study (2) . Most eyes, 5 developed signs and symptoms while the patients' authors agree that alpha-hemolytic streptococci and Staphother eyes were being treated. Cultures of the originally ylococcus sp. are probably not pathogens since they are affected eyes of these patients yielded H. influenzae (two), found with equal or greater frequency in normal eyes, but Staphylococcus aureus (one), and no pathogens (two).
these reports do not comment on possible quantitative Adverse events interpreted as probably due to the admindifferences in the cultures (2, 6). Our study did not provide istration of the study drug were rare in this investigation. Of convincing evidence that even specified numbers of these the 60 patients treated with norfloxacin, 2 had inflammation organisms clarify their role as pathogens. The status of reported. In one patient, the inflammation persisted for Staphylococcus aureus is also somewhat unclear, with some several days after drug therapy was discontinued. One studies showing an insignificant difference in isolation from patient treated with norfloxacin had stinging when the drug affected and normal eyes (2, 6 (2, 13) . In our study, all patients with pathogens isolated did well regardless of which topical agent was used. Although most S. pneumoniae and alpha-hemolytic streptococci were resistant in vitro to tobramycin, no patient with these organisms failed to improve. This outcome may have been due to high levels of the drug at the site of infection or to the self-limited nature of many cases of conjunctivitis. Perhaps slightly supportive of the first hypothesis is the fact that most such organisms were actually eradicated.
The effect of antimicrobial therapy for bacterial conjunctivitis, especially in adults, has not been extensively evaluated. One study in adults enrolled 143 patients, 43 of whom yielded pathogens on culture (11) . In this study, topical therapy with dexamethasone alone, dexamethasone in conjunction with neomycin and polymyxin B, or the antimicrobial agents alone was more effective than was placebo. In fact, placebo treatment for 21 of 26 eyes was stopped because the investigator felt that the patients' condition was appreciably worse on a follow-up visit. Interestingly, antibiotics alone were not more effective than corticosteroidcontaining regimens and did not control inflammation as rapidly. In a pediatric study which did not include use of corticosteroids, the combination of topical polymyxin and bacitracin was more effective and more rapidly effective in producing clinical resolution and bacterial eradication than was placebo (5) . In this study, 62% of treated patients with proven bacterial conjunctivitis were clinically cured by day 5, compared with 28% of patients given placebo (P < 0.02). Bacterial eradication at the same time was achieved in 71 versus 19% (P < 0.001). Although in our study no placebo was used, the rapid and favorable response seen in patients with bacterial conjunctivitis suggests that both agents were effective. The absence of any serious drug-associated side effects suggests that both norfloxacin and tobramycin are relatively safe when used in this manner.
The bacteriologic findings with external eye infections, primarily conjunctivitis, in our study are similar to those in other reports (2, 5, 6, 10, 13; Levin et al., J. Pediatr. 98:531, 1981). We did isolate adenovirus and herpes simplex virus as well but no chlamydiae (3). These agents are not well addressed by conventional antimicrobial agents used for treating conjunctivitis. Neither are anaerobes, which we did not culture for in our study. Notably, in our series and in several others, 30 to 70% of patients have had no pathogens identified (2, 6, 10) . These patients may have had chemical irritation, allergy, anaerobic or viral infection, or a variety of other inflammatory conditions. Regardless of cause, however, our patients without documented aerobic bacterial infections also did very well during the period of observation.
Our results show that a clinical diagnosis of bacterial conjunctivitis is often, but not always, correct and that norfloxacin ophthalmic solution seems to be a safe, effective, and appropriate agent for the treatment of certain types of external ocular infections.
